Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
| Molecular Weight | 553.4 g/mol |
|---|---|
| Molecular Formula | C23H30Cl2N8O4 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 8 |
| Exact Mass | 552.1767069 g/mol |
| Monoisotopic Mass | 552.1767069 g/mol |
| Topological Polar Surface Area | 140 A^2 |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 796 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
About the Company : Wuhan Sun-shine chemical Corporation Limited (Shanghai Sun-shine Chemical Technology Corporation Limited) is a high-tech enterprise engaged inR&D and sales of related compounds of ...
About the Company : Wuhan Sun-shine chemical Corporation Limited (Shanghai Sun-shine Chemical Technology Corporation Limited) is a high-tech enterprise engaged inR&D and sales of related compounds of ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Aliqopa® (copanlisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies and now work with the FDA on a voluntary withdrawal.
Lead Product(s): Copanlisib
Therapeutic Area: Oncology Brand Name: Aliqopa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Lead Product(s) : Copanlisib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer Provides Update on Aliqopa® (copanlisib)
Details : Aliqopa® (copanlisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies and now work with the FDA on a voluntary withdrawal.
Brand Name : Aliqopa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Details:
In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma, the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death compared to rituximab and placebo.
Lead Product(s): Copanlisib,Rituximab
Therapeutic Area: Oncology Brand Name: Aliqopa
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2021
Lead Product(s) : Copanlisib,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma, the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death compared to rituximab and placebo.
Brand Name : Aliqopa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 10, 2021
Details:
Phase III study CHRONOS-3 in patients with relapsed indolent Non-Hodgkin's Lymphoma (iNHL) who have received one or more prior lines of rituximab-containing therapy meets primary endpoint of progression-free survival .
Lead Product(s): Copanlisib,Rituximab
Therapeutic Area: Oncology Brand Name: Aliqopa
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Lead Product(s) : Copanlisib,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aliqopa™ (copanlisib) in Combination With Rituximab Meets Primary Endpoint in Patients With Rela...
Details : Phase III study CHRONOS-3 in patients with relapsed indolent Non-Hodgkin's Lymphoma (iNHL) who have received one or more prior lines of rituximab-containing therapy meets primary endpoint of progression-free survival .
Brand Name : Aliqopa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
4-(3-Chloropropyl) Morpholine Hydrochloride
CAS Number : 57616-74-7
End Use API : Copanlisib
About The Company : Shree Ganesh Remedies is established Since 1995 with an aim to manufacture, supply and export best quality of Pharmaceutical-intermediates, Bulk drugs and Speci...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
APIs
Reply
25 Jun 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Comment (7)
